Session Description
During this case conference, Dr. David Flannery, Director of Telegenetics and Digital Genetics at Cleveland Clinic’s Center for Personalized Genetic Healthcare, will be presenting about a telemedicine genetic consult from his apartment to a mission clinic in Honduras. Dr. Flannery will demonstrate how he was able to connect with the telemedicine cart and peripheral devices from the internet, provided by satellite, to the clinic. After Dr. Flannery’s case presentation, Ms. Alisha Keehn and Ms. Megan Lyon, Associate Program Director and Project Manager for the NCC, respectively, will share resources, tools, and trainings that have been developed by the seven Regional Genetics Networks (RGNs), National Genetics Education and Family Support Center (Family Center), and NCC to support genetics providers who utilize telemedicine.
Learning Objectives
At the conclusion of this session, participants should be able to:
- Describe how telemedicine can be utilized in clinical genetic evaluation for individuals with dysmorphic features.
- Identify telegenetic resources developed by the RGNs, Family Center, or NCC that can be utilized by genetics providers.
- Identify the RGN in which you practice genetics.
Faculty:
David Flannery, MD, FACMG
Director of Telegenetics and Digital Genetics, Cleveland Clinic Center for Personalized Genetic Healthcare
Alisha Keehn, MPA
Associate Project Director, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG
Megan Lyon, MPH
Project Manager, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG
Educational Credits are not offered
Target Audience
- Clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems.
- Laboratory directors and technicians who conduct genetic testing, researchers involved in the discovery of genetic disorders and treatments and any healthcare and public health professionals who have an in interest medical and clinical genetics and genomics.
Off-label Drug Use statement
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.
Disclosures of Financial Relationships
Staff - American College of Medical Genetics and Genomics
The following have nothing to disclose.
Jane Radford, MHA, CHCP
Claudia Barnett
Maximilian Muenke, MD, FACMG
Presenter Disclosures
David Flannery, MD, FACMG
Director of Telegenetics and Digital Genetics, Cleveland Clinic Center for Personalized Genetic Healthcare
Has no relevant financial relationships to disclose.
Alisha Keehn, MPA
Associate Project Director, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG
Has no relevant financial relationships to disclose.
Megan Lyon, MPH
Project Manager, National Coordinating Center for the Regional Genetics Networks (NCC), ACMG
Has no relevant financial relationships to disclose.